GeneScience Pharmaceutical drugs added to national medical insurance catalog

Changchun High & New Technology Industry Group announced that two drugs from its controlled subsidiary, Changchun GeneScience Pharmaceutical Co., Ltd. ("GeneScience Pharmaceutical"), have been newly included in the National Medical Insurance Catalog. The inclusion is effective from January 1, 2026, until December 31, 2027. The drugs are Jinsaizeng (a long-acting growth hormone) and Meishiya (Megestrol Acetate Oral Suspension).

Jinsaizeng is approved for pediatric growth disorders due to endogenous growth hormone deficiency, Turner syndrome, and idiopathic short stature. Meishiya is indicated for the treatment of anorexia and significant weight loss in patients with acquired immunodeficiency syndrome and cancer cachexia.

The company expects the inclusion of these drugs to boost their market promotion and sales volume, acknowledging their clinical value and innovation. The impact on its operating performance is currently difficult to estimate, and the company advises investors to exercise caution due to pending execution details from government departments.